Business
Starpharma hunts for cash as it speeds up COVID nasal spray treatment – Sydney Morning Herald
The Melbourne biotech is in a trading halt as it launches a placement for a COVID treatment it hopes to be ready by next year.
Starpharma shares have been on a tear over the past month since the business started to update the market on progress about the nasal spray. Shares have jumped from $1.41 to $1.60 over the past month.
The nasal spray repurposes Starpharma’s antiviral product SPL7013, which is already used in its sexual health products including condoms. The company hopes the compound will bind to the SARS-COV-2 spike protein and block the virus from attaching to cells.
Earlier this month the company released d…
-
Noosa News22 hours agoGyrocopter pilot injured in crash-landing on K’Gari, north of Brisbane
-
General24 hours agoTruck driver charged with causing death by dangerous driving after highway crash
-
Noosa News13 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General9 hours agoChoosing an online exercise program can be confusing. Here’s what to look out for